Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph G Zinner

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Clinical Lung Cancer|May 1, 2004
Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical dataRalph G Zinner, Roy S Herbst
Cureus|July 6, 2026
Asymptomatic Pembrolizumab-Associated HypertriglyceridemiaLauren S Yeager, Ralph G Zinner, Zhonglin Hao
Lung Cancer (Amsterdam, Netherlands)|June 12, 2002
Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary resultsRalph G Zinner, Jeri Kim, Roy S Herbst
Clinics in Geriatric Medicine|October 10, 2017
Lung Cancer in the Older PatientJulie A Barta, Ralph G Zinner, Michael Unger
Oncology (Williston Park, N.Y.)|September 2, 2004
Pemetrexed in advanced NSCLC: a review of the clinical dataRalph G Zinner, Frank V Fossella, Roy S Herbst
Journal of the Royal Statistical Society. Series C, Applied Statistics|March 4, 2017
Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal OutcomesPeter F Thall, Hoang Q Nguyen, Ralph G Zinner
Mayo Clinic Proceedings|December 25, 2025
Uncovering Hidden Marginalized Populations in Lung Cancer Screening via Latent Class AnalysisToru Yoshino, Sae X Morita, Ralph G Zinner, et al.
Clinical Lung Cancer|March 5, 2010
Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trialsRalph G Zinner, Silvia Novello, Guangbin Peng, et al.
Clinical Lung Cancer|September 15, 2010
Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histologyRalph G Zinner, Scott B Saxman, Guangbin Peng, et al.
Clinical Lung Cancer|October 30, 2018
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of CareJyoti D Patel, Luis Paz-Ares, Ralph G Zinner, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Clinical Lung Cancer|May 1, 2004
Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical dataRalph G Zinner, Roy S Herbst
Cureus|July 6, 2026
Asymptomatic Pembrolizumab-Associated HypertriglyceridemiaLauren S Yeager, Ralph G Zinner, Zhonglin Hao
Lung Cancer (Amsterdam, Netherlands)|June 12, 2002
Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary resultsRalph G Zinner, Jeri Kim, Roy S Herbst
Clinics in Geriatric Medicine|October 10, 2017
Lung Cancer in the Older PatientJulie A Barta, Ralph G Zinner, Michael Unger
Oncology (Williston Park, N.Y.)|September 2, 2004
Pemetrexed in advanced NSCLC: a review of the clinical dataRalph G Zinner, Frank V Fossella, Roy S Herbst
Journal of the Royal Statistical Society. Series C, Applied Statistics|March 4, 2017
Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal OutcomesPeter F Thall, Hoang Q Nguyen, Ralph G Zinner
Mayo Clinic Proceedings|December 25, 2025
Uncovering Hidden Marginalized Populations in Lung Cancer Screening via Latent Class AnalysisToru Yoshino, Sae X Morita, Ralph G Zinner, et al.
Clinical Lung Cancer|March 5, 2010
Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trialsRalph G Zinner, Silvia Novello, Guangbin Peng, et al.
Clinical Lung Cancer|September 15, 2010
Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histologyRalph G Zinner, Scott B Saxman, Guangbin Peng, et al.
Clinical Lung Cancer|October 30, 2018
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of CareJyoti D Patel, Luis Paz-Ares, Ralph G Zinner, et al.
Pageof 5